#OnlineFirst : Sequential #chemoimmunotherapy in #gastriccancer , by minae an, Arnav Mehta, Byung Hoon Min, You Jeong Heo, Seung Tae Kim, Sam Klempner, Jeeyun Lee MD et al.
bit.ly/3wbc76g
Mass General Cancer Center @Broadinstitute #SamsungMedicalCenter SU2Cscience

Congrats Martin. This is an excellent work.
Hope we can use this test in the clinic someday.

Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker aacrjournals.org/cancerdiscover…

Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. Accurate, fast and cheap ($3) assay detected this endogenous retroviral protein ORF1p in blood of patients with a variety of cancers: Ovarian, esophageal, CRC, etc. aacrjournals.org/cancerdiscover…

Great talk of Jeeyun Lee MD on ctDNA in gastric cancer: from theory to clinical translation at #ESMO23 ESMO - Eur. Oncology Lizzy Smyth Kohei shitara

Prof Jeeyun Lee MD highlighting biomarker platform based research in GC; use of liquid bio markers; discordant HER 2 expression IHC v cfDNA #ESMO23 #GI

Nice paper in Nature Genetics building on determinants of response in dMMR cancers from Jacks Lab. Nice to see reanalysis of our Cancer Discovery work in dMMR gastric from minae an and Jeeyun Lee MD

rdcu.be/dmhA7 -- Nature Genetics paper

Honored to be invited by KSMO23 to share our work! Looking forward to collaborations with Wungki Park, MD MS Memorial Sloan Kettering Cancer Center
and the amazing scientific community in Korea

Got a gift from Korean Society of Medical Oncology and information about KSMO 2023. #ASCO23

Looking forward to seeing the KEYNOTE 811 results at #ESMO 2023

✅ PFS endpoint met for **PD-L1 ➕ only**
❓OS.. trend but not there yet...

FDA label being amended for PD-L1 status; EMA right to wait?

Deepening our international gastric cancer collaborations with Jeeyun Lee MD and her team. Pleasure to host talented post docs Dr. Minae An and Dr. Jaeyun Jung at Mass General Cancer Center Arnav Mehta minae an
See their recent preprint here medrxiv.org/content/10.110…

We invite you to our Forum for Precision Oncology at SMC.
It is free and both online and offline. March 31st 2023.
protect2.fireeye.com/v1/url?k=f3a9e…

Korean researchers at AACR 2023! Don't miss the ultimate networking event! Join us on Sunday April 16th at Hyatt Regency Orlando for an evening of community-building and celebration. Register now to secure your spot!
#AACR23 #KSMO #KCA #KoreanNight
docs.google.com/forms/d/1MyJyL…

Good to see my colleagues Yelena Y. Janjigian MD and Sam Klempner Aki Smith and gastric cancer survivors. My patient who was a superb 40 year old neurologist died of stomach cancer few days ago after a 6 year fight. I promise we will do better.

$MRK Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma - businesswire.com/news/home/2022…

Transitioning from #clinicaltrial -centric studies to #patient -centric trials, to bring #PrecisionOncology to the global patient community.

Our phase Ib/II trial testing triplet regimen (trastuzumab, pembrolizumab, chemotherapy) as 1L Tx for HER2(+) AGC (PANTHERA trial) is finally published!
#YonseiCancerCenter #HER2 #AGC Nature Communications

Treatment with tumor-infiltrating
lymphocytes (TIL) 🆚 ipilimumab for advanced melanoma bu Dr. J Haanen
🔸80% received prior IO
🔸Study met PFS endpoint! 20% CR
🔸>G3+ AEs Almost all patients!
ESMO - Eur. Oncology #ESMO22 OncoAlert

dMMR/MSI-High Advanced #ColonCancer with response to single agent #immunotherapy in a nonagenarian. Just 1 dose & the #cancer is melting away.
#ctDNA has turned from➕➡️➖.
Plasma-MSI also initially “high” & now “not detectable”. Will become a non-surgical disease. #WatchANDWait

New #JITC article: Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer bit.ly/3ONdKeF Jeeyun Lee MD 안용

#OpenAccess in Cancer Discovery;
AACR Project GENIE: 100,000 Cases and Beyond
aacrjournals.org/cancerdiscover…
A deep dive into the data infrastructure & translational/clinical applications of this giant AACR consortium (>110,000 tumors accrued from 19 cancer centers globally).
Amazing effort!